197 Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D-CTFR mutation: data from the ENVISION study

How Clinically Efficient Are Lumacaftor/Ivacaftor for Cystic Fibrosis Patients: An Updated Literature Review

“…However, the IVA group reflected the increasing trend in height 0.00 at BL, 0.11 at 24 weeks, P<0.01 and 0.17 at 48 weeks, P<0.001, and weight z-score 0.08 at BL and 0.44 at 48-weeks, P<0.001. The height velocities increased in the IVA-treated group as compared to the placebo group [ 32 ].…”

“…However, the IVA group reflected the increasing trend in height 0.00 at BL, 0.11 at 24 weeks, P<0.01 and 0.17 at 48 weeks, P<0.001, and weight z-score 0.08 at BL and 0.44 at 48-weeks, P<0.001. The height velocities increased in the IVA-treated group as compared to the placebo group[32].In their clinical trial, Salvatore et al had attained improved BMI, CFQ-R, FVC, and FEV1[33]. Volkova et al studied the IVA's combined effects in an observational study that compared IVA with a comparator (COMP) group in 2016.…”